JP2023543439A - ＮＦ－κＢ媒介疾患の処置 - Google Patents

ＮＦ－κＢ媒介疾患の処置 Download PDF

Info

Publication number
JP2023543439A
JP2023543439A JP2023518416A JP2023518416A JP2023543439A JP 2023543439 A JP2023543439 A JP 2023543439A JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023518416 A JP2023518416 A JP 2023518416A JP 2023543439 A JP2023543439 A JP 2023543439A
Authority
JP
Japan
Prior art keywords
day
human patient
vamorolone
muscular dystrophy
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543439A5 (https=
Inventor
ダマスカール ジェシー
ホフマン エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reveragen Biopharma Inc
Original Assignee
Reveragen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reveragen Biopharma Inc filed Critical Reveragen Biopharma Inc
Publication of JP2023543439A publication Critical patent/JP2023543439A/ja
Publication of JP2023543439A5 publication Critical patent/JP2023543439A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023518416A 2020-09-21 2021-09-21 ＮＦ－κＢ媒介疾患の処置 Pending JP2023543439A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063081073P 2020-09-21 2020-09-21
US63/081,073 2020-09-21
US202163195473P 2021-06-01 2021-06-01
US63/195,473 2021-06-01
US202163214908P 2021-06-25 2021-06-25
US63/214,908 2021-06-25
PCT/US2021/051274 WO2022061287A1 (en) 2020-09-21 2021-09-21 TREATMENT OF NF-κB-MEDIATED DISEASE

Publications (2)

Publication Number Publication Date
JP2023543439A true JP2023543439A (ja) 2023-10-16
JP2023543439A5 JP2023543439A5 (https=) 2024-10-01

Family

ID=80776432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518416A Pending JP2023543439A (ja) 2020-09-21 2021-09-21 ＮＦ－κＢ媒介疾患の処置

Country Status (9)

Country Link
US (2) US20220184098A1 (https=)
EP (1) EP4213855A4 (https=)
JP (1) JP2023543439A (https=)
KR (1) KR20230092905A (https=)
AU (1) AU2021343534A1 (https=)
CA (1) CA3170698A1 (https=)
IL (1) IL301500A (https=)
MX (1) MX2023003258A (https=)
WO (1) WO2022061287A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4436583A4 (en) * 2021-11-22 2025-04-02 ReveraGen BioPharma, Inc. TREATMENT OF NF-kB-MEDIATED DISEASE
WO2025199347A1 (en) * 2024-03-21 2025-09-25 Reveragen Biopharma, Inc. Treatment of glomerulonephritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504776A (ja) * 2005-08-18 2009-02-05 アクセラロクス， インコーポレイテッド アラキドン酸代謝経路またはシグナル伝達経路を調節することによる骨を処置するための方法
JP2018526394A (ja) * 2015-09-08 2018-09-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 注意欠陥障害及び２２ｑ症候群の治療のための非選択的代謝型グルタメート受容体アクチベーター
US20200148717A1 (en) * 2011-11-29 2020-05-14 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of nf-kappa beta for treatment of disease
US20200281942A1 (en) * 2019-03-07 2020-09-10 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504776A (ja) * 2005-08-18 2009-02-05 アクセラロクス， インコーポレイテッド アラキドン酸代謝経路またはシグナル伝達経路を調節することによる骨を処置するための方法
US20200148717A1 (en) * 2011-11-29 2020-05-14 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of nf-kappa beta for treatment of disease
JP2018526394A (ja) * 2015-09-08 2018-09-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 注意欠陥障害及び２２ｑ症候群の治療のための非選択的代謝型グルタメート受容体アクチベーター
US20200281942A1 (en) * 2019-03-07 2020-09-10 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEIER, C. R. ET AL.: "VBP15, a novel anti‐inflammatory and membrane‐stabilizer, improves muscular dystrophy without side", EMBO MOLECULAR MEDICINE, vol. 5, JPN6025041105, 2013, pages 1569 - 1585, ISSN: 0005703133 *
HOFFMAN, E. P. ET AL.: "Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function", NEUROLOGY, vol. 93, JPN6025041104, 2019, pages 1312 - 1323, ISSN: 0005703132 *

Also Published As

Publication number Publication date
WO2022061287A1 (en) 2022-03-24
AU2021343534A1 (en) 2023-05-11
KR20230092905A (ko) 2023-06-26
US20220184098A1 (en) 2022-06-16
CA3170698A1 (en) 2022-03-24
MX2023003258A (es) 2023-05-08
IL301500A (en) 2023-05-01
EP4213855A4 (en) 2024-10-23
EP4213855A1 (en) 2023-07-26
US20240139210A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US20240139210A1 (en) Treatment of nf-kb-mediated disease
AU2016342375B2 (en) Analogs of celastrol
JP7819094B2 (ja) ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法
JP2021502403A5 (https=)
JP2023530084A (ja) ４－（２－クロロ－４－メトキシ－５－メチルフェニル）－ｎ－［（１ｓ）－２－シクロプロピル－１－（３－フルオロ－４－メチルフェニル）エチル］－５－メチル－ｎ－プロパ－２－イニル－１，３－チアゾール－２－アミンの調製のための合成法
US20240245711A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
AU2020377204A1 (en) The use of a splicing modulator for a treatment slowing progression of huntington's disease
JP2010513316A (ja) （ｒ）−プラミペキソール組成物およびその使用法
TW202114695A (zh) 用於治療cns病症之組合物及方法
EP3145513B1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
TW202114700A (zh) 用於治療cns病症之組合物及方法
KR20200040761A (ko) 코티코트로핀 방출 인자 수용체 길항제
JP2005526077A (ja) 神経防御性スピロステノール医薬組成物
CN1292701A (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
US20240299416A1 (en) TREATMENT OF NF-kB-MEDIATED DISEASE
US20200316021A1 (en) Dosing Regimen of Siponimod
EP3044192B1 (en) Deuterated compounds
JP2019530711A (ja) アピリモド組成物およびそれをアルツハイマー病の処置に使用するための方法
US20240226117A1 (en) Treatment of congenital adrenal hypoplasia
CN107709326B (zh) 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶
CN116507338A (zh) NF-κB介导的疾病的治疗
US20160264525A1 (en) Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea
RU2776845C2 (ru) Аналоги целастрола
AU2020324937B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403